MET and colorectal carcinoma: MET was discovered to be overexpressed in primary CRC, found in about 1.7% of all CRCs (Raghav et al., 2016), indicating it could be an important prognostic marker for early-stage invasion and regional disease metastasis (Takeuchi et al., 2003).